{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:01:24Z","timestamp":1778637684514,"version":"3.51.4"},"reference-count":112,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>At the moment, there are no U.S. Food and Drug Administration (U.S. FDA)-approved drugs for the treatment of COVID-19, although several antiviral drugs are available for repurposing. Many of these drugs suffer from polymorphic transformations with changes in the drug\u2019s safety and efficacy; many are poorly soluble, poorly bioavailable drugs. Current tools to reformulate antiviral APIs into safer and more bioavailable forms include pharmaceutical salts and cocrystals, even though it is difficult to classify solid forms into these regulatory-wise mutually exclusive categories. Pure liquid salt forms of APIs, ionic liquids that incorporate APIs into their structures (API-ILs) present all the advantages that salt forms provide from a pharmaceutical standpoint, without being subject to solid-state matter problems. In this perspective article, the myths and the most voiced concerns holding back implementation of API-ILs are examined, and two case studies of API-ILs antivirals (the amphoteric acyclovir and GSK2838232) are presented in detail, with a focus on drug property improvement. We advocate that the industry should consider the advantages of API-ILs which could be the genesis of disruptive innovation and believe that in order for the industry to grow and develop, the industry should be comfortable with a certain element of risk because progress often only comes from trying something different.<\/jats:p>","DOI":"10.3390\/ijms21176002","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T09:35:31Z","timestamp":1597916131000},"page":"6002","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Are Myths and Preconceptions Preventing Us from Applying Ionic Liquid Forms of Antiviral Medicines to the Current Health Crisis?"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0708-764X","authenticated-orcid":false,"given":"Julia L.","family":"Shamshina","sequence":"first","affiliation":[{"name":"525 Solutions, Inc., P. O. Box 2206, Tuscaloosa, AL 35403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9843-7494","authenticated-orcid":false,"given":"Robin D.","family":"Rogers","sequence":"additional","affiliation":[{"name":"525 Solutions, Inc., P. O. Box 2206, Tuscaloosa, AL 35403, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"ref_1","unstructured":"(2020, June 29). Potential Antiviral Drugs under Evaluation for the Treatment of COVID-19, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/."},{"key":"ref_2","unstructured":"(2020, June 29). COVID-19: Prevention & Investigational Treatments, Available online: https:\/\/www.drugs.com\/condition\/covid-19.htmlhttps:\/\/www.covid19treatmentguidelines.nih.gov\/antiviral-therapy\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.oprd.0c00233","article-title":"Quest for a COVID-19 Cure by repurposing small-molecule drugs: Mechanism of action, clinical development, synthesis at scale, and outlook for supply","volume":"24","author":"Hughes","year":"2020","journal-title":"Org. Process Res. Dev."},{"key":"ref_4","first-page":"318","article-title":"Thermoanalytical and crystallographic methods","volume":"Volume 192","author":"Brittain","year":"2009","journal-title":"Polymorphism in Pharmaceutical Solids. Drugs and the Pharmaceutical Sciences Series"},{"key":"ref_5","unstructured":"(2020, June 29). Characteristics of Potential Antiviral Agents under Evaluation for Treatment of COVID-19, Available online: https:\/\/www.covid19treatmentguidelines.nih.gov\/tables\/table-2b\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/528188a","article-title":"Chemistry: Develop ionic liquid drugs","volume":"528","author":"Shamshina","year":"2015","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/chem.200601243","article-title":"Synthesis and properties of trigeminal tricationic ionic liquids","volume":"13","author":"Pernak","year":"2007","journal-title":"Chem Eur. J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, W., and Cue, B. (2018). Ionic liquids in the pharmaceutical industry. Green Techniques for Organic Synthesis and Medicinal Chemistry, John Wiley and Sons. [2nd ed.].","DOI":"10.1002\/9781119288152"},{"key":"ref_9","unstructured":"Bernstein, J. (2002). Polymorphism in Molecular Crystals, IUCR Monographs on Crystallography 14, Oxford Science Publications."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1073\/pnas.0437744100","article-title":"Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization","volume":"100","author":"Morissette","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","unstructured":"Bandi, P.P.R., Kura, R.R., Rapoli, R.R., Dasari, M.R., and Kesireddy, S.C.R. (2009). Novel polymorphs of Lopinair. (U.S. Patent 13,121,505)."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"c292","DOI":"10.1107\/S0108767305087532","article-title":"Two polymorphs\u2014Which one is stable at ambient conditions?","volume":"A61","author":"Jensen","year":"2005","journal-title":"Acta Cryst."},{"key":"ref_13","unstructured":"Odendaal, R.W. (2012). Amorphism and Polymorphism of Azithromycin. [Ph.D. Thesis, North West University]. Available online: https:\/\/repository.nwu.ac.za\/handle\/10394\/9528."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/15421406.2011.556472","article-title":"Studies on crystal modifications of Ganciclovir","volume":"537","author":"Sarbajna","year":"2011","journal-title":"Mol. Cryst. Liquid Cryst."},{"key":"ref_15","first-page":"1116","article-title":"Polymorphs of the antiviral drug ganciclovir","volume":"C73","author":"Guzei","year":"2017","journal-title":"Acta Cryst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/jps.22336","article-title":"Polymorphs and hydrates of Acyclovir","volume":"100","author":"Lutker","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8172","DOI":"10.1039\/C6CE01975G","article-title":"Polymorphism of the antiviral agent clevudine","volume":"18","author":"Noonan","year":"2016","journal-title":"Cryst. Eng. Comm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ceat.200500397","article-title":"Polymorphism of active pharmaceutical ingredients","volume":"29","author":"Karpinski","year":"2006","journal-title":"Chem. Eng. Technol."},{"key":"ref_19","first-page":"9","article-title":"Challenges in polymorphism of pharmaceuticals","volume":"5","author":"Chawla","year":"2004","journal-title":"CRIPS"},{"key":"ref_20","first-page":"10","article-title":"Polymorphism: The phenomenon affecting the performance of drugs","volume":"1","author":"Raza","year":"2014","journal-title":"SOJ Pharm. Pharm. Sci."},{"key":"ref_21","unstructured":"FDA Guidance for Industry (2020, June 29). ANDAs: Pharmaceutical Solid Polymorphism. Chemistry, Manufacturing, and Controls Information, Available online: https:\/\/www.fda.gov\/media\/71375\/download."},{"key":"ref_22","unstructured":"Brittain, H.G. (2009). Approaches to high-throughput physical form screening and discovery. Polymorphism in Pharmaceutical Solids, Informa Healthcare."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1107\/S0021889804000391","article-title":"High-throughput powder diffraction. II. Applications of clustering methods and multivariate data analysis","volume":"37","author":"Barr","year":"2004","journal-title":"J. Appl. Crystallography."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2174\/138161205774414510","article-title":"Why drugs fail\u2014A study on side effects in new chemical entities","volume":"11","author":"Schuster","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104505\/1","DOI":"10.1063\/1.3223540","article-title":"Study of molecular dynamics of pharmaceutically important protic ionic liquid-verapamil hydrochloride. I. Test of thermodynamic scaling","volume":"131","author":"Wojnarowska","year":"2009","journal-title":"J. Chem. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1002\/jps.24508","article-title":"Zanamivir amidoxime- and N-hydroxyguanidine-based prodrug approaches to tackle poor oral bioavailability","volume":"104","author":"Schade","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_27","first-page":"78","article-title":"Acyclovir sodium potential as an antiviral drug is limited by its low oral bioavailability (20\u201330%) with short half-life (2\u20133 h) with poor plasma protein binding. Formulation and evaluation of Acyclovir sodium solid lipid microparticles","volume":"4","author":"Nagappa","year":"2016","journal-title":"Am. J. Adv. Drug Deliv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1021\/acs.jmedchem.6b00428","article-title":"Reduction sensitive lipid conjugates of tenofovir: Synthesis, stability, and antiviral activity","volume":"59","author":"Giesler","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.drudis.2006.03.004","article-title":"Biological assay challenges from compound solubility: Strategies for bioassay optimization (Review)","volume":"11","author":"Di","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.1021\/jm701032y","article-title":"Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database","volume":"50","author":"Paulekuhn","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.22735","article-title":"A survey of top 200 drugs\u2014Inconsistent practice of drug strength expression for drugs containing salt forms","volume":"101","author":"Prohotsky","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1039\/b313552g","article-title":"Crystal and co-crystal","volume":"5","author":"Desiraju","year":"2003","journal-title":"CrystEngComm"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1021\/acs.cgd.8b00933","article-title":"Creating cocrystals: A review of pharmaceutical cocrystal preparation routes and applications","volume":"18","author":"Padrela","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1021\/cg050125l","article-title":"Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities","volume":"5","author":"Banerjee","year":"2005","journal-title":"Cryst. Growth Des."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.26452\/ijrps.v10i4.1589","article-title":"Better in solubility enhancement: Salt or cocrystal?","volume":"10","author":"Sopyan","year":"2019","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"ref_36","unstructured":"(2020, July 13). Guidance for Industry on Regulatory Classification of Pharmaceutical Co-Crystals, Available online: https:\/\/www.federalregister.gov\/documents\/2013\/04\/26\/2013-09872\/guidance-for-industry-on-regulatory-classification-of-pharmaceutical-co-crystals-availability."},{"key":"ref_37","unstructured":"(2020, July 13). Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/81824\/download."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/cg3002948","article-title":"Polymorphs, salts, and cocrystals: What\u2019s in a name?","volume":"12","author":"Aitipamula","year":"2012","journal-title":"Crystal Growth Des."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/cg4000439","article-title":"Understanding the effects of ionicity in salts, solvates, co-crystals, Ionic co-crystals, and ionic liquids, rather than nomenclature, is critical to understanding their behavior","volume":"13","author":"Kelley","year":"2013","journal-title":"Crystal Growth Des."},{"key":"ref_40","first-page":"1","article-title":"Principles of salt formation","volume":"2","author":"Makary","year":"2014","journal-title":"UK J. Pharm. Biosci."},{"key":"ref_41","first-page":"41","article-title":"Polymorphism in the pharmaceutical industry","volume":"21","author":"Hilfiker","year":"2006","journal-title":"Chem Today"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0378-5173(86)90055-4","article-title":"Salt selection for basic drugs","volume":"33","author":"Gould","year":"1986","journal-title":"Int. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Gupta, D., Bhatia, D., Dave, V., Sutariya, V., and Varghese Gupta, S. (2018). Salts of therapeutic agents: Chemical, physicochemical, and biological considerations. Molecules, 23.","DOI":"10.20944\/preprints201804.0187.v1"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1039\/b706677p","article-title":"The third evolution of ionic liquids: Active pharmaceutical ingredients","volume":"31","author":"Hough","year":"2007","journal-title":"New J. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1021\/cr980032t","article-title":"Room-temperature ionic liquids. Solvents for synthesis and catalysis","volume":"99","author":"Welton","year":"1999","journal-title":"Chem. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1039\/C5MD00290G","article-title":"Sulfasalazine in ionic liquid form with improved solubility and exposure","volume":"6","author":"Shadid","year":"2015","journal-title":"Med. Chem. Comm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1021\/acsomega.7b00554","article-title":"Acyclovir as an ionic liquid cation or anion can improve aqueous solubility","volume":"2","author":"Shamshina","year":"2017","journal-title":"Acs Omega"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"28126","DOI":"10.1039\/C3RA47615D","article-title":"Cholinium-based ionic liquids with pharmaceutically active anions","volume":"4","author":"Florindo","year":"2014","journal-title":"RSC Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/acs.chemrev.6b00562","article-title":"Biological activity of ionic liquids and their application in pharmaceutics and medicine","volume":"117","author":"Egorova","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1517\/17425247.2013.808185","article-title":"Ionic liquids in drug delivery","volume":"10","author":"Shamshina","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1039\/C4SC01036A","article-title":"Simultaneous membrane transport of two active pharmaceutical ingredients by charge assisted hydrogen bond complex formation","volume":"5","author":"Wang","year":"2014","journal-title":"Chem. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejpb.2016.03.003","article-title":"Lidocaine self-sacrificially improves the skin permeation of the acidic and poorly water-soluble drug Etodolac via its transformation into an ionic liquid","volume":"102","author":"Miwa","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_53","unstructured":"Clinical trials (2020, July 20). Etodolac-Lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02695381."},{"key":"ref_54","unstructured":"(2020, July 20). Topline Phase III Clinical Trial Results for ETOREAT\u00ae in the United States. Available online: http:\/\/pdf.irpocket.com\/C4586\/xAmX\/x8qh\/SVn5.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kfx172","article-title":"Scaling-up ionic liquid-based technologies: How much do we care about their toxicity? Prima facie information on 1-ethyl-3-methylimidazolium acetate","volume":"161","author":"Ostadjoo","year":"2018","journal-title":"Toxicol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Peplow, M. (2005). Warning shot for green chemistry. Nature.","DOI":"10.1038\/news051031-8"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.watres.2009.09.030","article-title":"Environmental fate and toxicity of ionic liquids: A review","volume":"44","author":"Pham","year":"2010","journal-title":"Water Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejpb.2015.05.027","article-title":"\u2018Pro et contra\u2019 ionic liquid drugs\u2014Challenges and opportunities for pharmaceutical translation","volume":"94","author":"Balk","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_59","unstructured":"(2020, June 30). FDA Guidance Document \u201cOral Solutions and Suspensions (8\/94)\u201d, Available online: https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/inspection-guides\/oral-solutions-and-suspensions-894."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1021\/ci500206u","article-title":"Viscosity of ionic liquids: An extensive database and a new group contribution model based on a feed-forward artificial neural network","volume":"54","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"16207","DOI":"10.1039\/C9NJ03436F","article-title":"Prediction of the viscosity of imidazolium-based ionic liquids at different temperatures using the quantitative structure property relationship approach","volume":"43","author":"Koi","year":"2019","journal-title":"New J. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1039\/c3gc41389f","article-title":"Mixing ionic liquids \u2014\u201cSimple mixtures\u201d or \u201cdouble salts\u201d?","volume":"16","author":"Chatel","year":"2014","journal-title":"Green Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1039\/c3nj00454f","article-title":"Drug specific tuning of an ionic liquid\u2019s hydrophilic-lipophilic balance to improve water solubility of poorly soluble active pharmaceutical ingredients","volume":"37","author":"McCrary","year":"2013","journal-title":"New J. Chem."},{"key":"ref_64","unstructured":"(2020, July 15). Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug Substances and Products; Availability, Available online: https:\/\/www.federalregister.gov\/documents\/2013\/06\/20\/2013-14674\/guidance-for-industry-guidance-on-abbreviated-new-drug-applications-stability-testing-of-drug."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kadokawa, J.-I. (2013). Pharmaceutical salts: Solids to liquids by using ionic liquid design. Ionic Liquids\u2014New Aspects for the Future, InTechOpen.","DOI":"10.5772\/45605"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1039\/c2md00269h","article-title":"Development of novel ionic liquids based on ampicillin","volume":"3","author":"Ferraz","year":"2012","journal-title":"Med. Chem. Comm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1039\/B813213P","article-title":"Ionic liquids with dual biological function: Sweet and anti-microbial, hydrophobic quaternary ammonium-based salts","volume":"33","author":"Smiglak","year":"2009","journal-title":"New J. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1039\/b923855g","article-title":"In search of pure liquid salt forms of aspirin: Ionic liquid approaches with acetylsalicylic acid and salicylic acid","volume":"12","author":"Bica","year":"2012","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_69","unstructured":"Zhang, S. (2019). Biological activity of ionic liquids involving ionic and covalent binding: Tunable drug development platform. Encyclopedia of Ionic Liquids, Springer."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/mp5005993","article-title":"Molecular dynamics simulation study of the association of lidocainium docusate and its derivatives in aqueous solution","volume":"12","author":"Smith","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1039\/c1cc14314j","article-title":"Enhanced membrane transport of pharmaceutically active protic ionic liquids","volume":"47","author":"Stoimenovski","year":"2011","journal-title":"Chem. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1211\/0022357001774804","article-title":"Ion-pair formation as a strategy to enhance topical delivery of salicylic acid","volume":"52","author":"Megwa","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_73","unstructured":"(2020, July 15). U.S. FDA Current Good Manufacturing Practice (CGMP) Regulations, Available online: https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/current-good-manufacturing-practice-cgmp-regulations."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijpharm.2013.08.010","article-title":"Evaluation of solubility and partition properties of ampicillin-based ionic liquids","volume":"456","author":"Florindo","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1747-0285.2011.01114.x","article-title":"Design, synthesis, and biological evaluation of beta-lactam antibiotic-based imidazolium- and pyridinium-type ionic liquids","volume":"78","author":"Cole","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/jps.23487","article-title":"Synthesis, characterization, and liposome partition of a novel tetracycline derivative using the ionic liquids framework","volume":"102","author":"Alves","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11095-009-0030-0","article-title":"Crystalline vs. ionic liquid salt forms of active pharmaceutical ingredients: A position paper","volume":"27","author":"Stoimenovski","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"35735","DOI":"10.1039\/C9RA07731F","article-title":"Reorientation dynamics and ion diffusivity of neat dimethylimidazolium dimethylphosphate probed by NMR spectroscopy","volume":"9","author":"Wiedemann","year":"2019","journal-title":"RSC Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/cphc.201100927","article-title":"Structural studies on ionic liquid\/water\/peptide systems by HR-MAS NMR spectroscopy","volume":"13","author":"Richardt","year":"2012","journal-title":"ChemPhysChem"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.1021\/jp4078536","article-title":"1H NMR relaxometry, viscometry, and PFG NMR studies of magnetic and nonmagnetic ionic liquids","volume":"117","author":"Daniel","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"15411","DOI":"10.1021\/ja035783d","article-title":"Ionic liquids by proton transfer:\u2009 vapor pressure, conductivity, and the relevance of \u0394pKa from aqueous solutions","volume":"125","author":"Yoshizawa","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1039\/C4CP00804A","article-title":"Particle aggregation mechanisms in ionic liquids","volume":"16","author":"Szilagyi","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_83","first-page":"480","article-title":"Basics of compounding: Vehicles for compounded oral liquid medications: A review","volume":"22","author":"Cutaia","year":"2018","journal-title":"Int. J. Pharm. Comp."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijpharm.2005.03.028","article-title":"Novel anhydrous emulsions: Formulation as controlled release vehicles","volume":"298","author":"Suitthimeathegorn","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1208\/s12248-012-9411-0","article-title":"Generic development of topical dermatologic products: Formulation development, process development, and testing of topical dermatologic products","volume":"15","author":"Chang","year":"2013","journal-title":"Aaps J."},{"key":"ref_86","first-page":"e130","article-title":"Pharmaceutical applications of eutectic mixtures","volume":"2","author":"Gala","year":"2013","journal-title":"J. Dev. Drugs"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0024-3205(88)90150-6","article-title":"Drug solubilizers to aid pharmacologists: Amorphous cyclodextrin derivatives","volume":"43","author":"Pitha","year":"1988","journal-title":"Life Sci."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Riebesehl, B.U. (2015). Drug delivery with organic solvents or colloidal dispersed systems. The Practice of Medicinal Chemistry, Academic Press. [4th ed.].","DOI":"10.1016\/B978-0-12-417205-0.00029-8"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2015.10.068","article-title":"An investigation into moisture barrier film coating efficacy and its relevance to drug stability in solid dosage forms","volume":"497","author":"Mwesigwa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0378-5173(90)90221-O","article-title":"The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state","volume":"62","author":"Ahlneck","year":"1990","journal-title":"Int. J. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: Physiochemical and physiological issues and lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_92","unstructured":"Riisager, A., Fehrmann, R., Rodriguez, H., Bica, K., Rogers, R.D., Daly, D.T., and Gurau, G. (2011). Supported biologically active compounds. (WIPO (PCT) Patent WO2011110662A1)."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1039\/c2cc30959a","article-title":"Pharmaceutically active ionic liquids with solids handling, enhanced thermal stability, and fast release","volume":"48","author":"Bica","year":"2012","journal-title":"Chem. Commun."},{"key":"ref_94","unstructured":"(2020, July 15). All about Drugs: GSK 2838232. Available online: https:\/\/www.allfordrugs.com\/2016\/06\/13\/gsk-2838232\/."},{"key":"ref_95","unstructured":"Hatcher, M.A., Johns, B.A., Martin, M.T., Tabet, E.A., and Tang, J. (2013). Preparation of betulin derivatives for the treatment of HIV. (WIPO (PCT) Patent WO2013090664A1)."},{"key":"ref_96","unstructured":"Johns, B.A. (2015). Derivatives of betulin. (U.S. Patent US 9,102,685 B2)."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"DeJesus, E., Harward, S., Jewell, R.C., Johnson, M., Dumont, E., Wilches, V., Halliday, F., Talarico, C.L., Jeffrey, J., and Gan, J. (2019). A Phase IIa study evaluating safety, pharmacokinetics, and antiviral activity of GSK2838232, a novel, second-generation maturation inhibitor, in participants with human immunodeficiency virus type 1 infection. Clin. Infect. Dis., Pii: ciz938.","DOI":"10.1093\/cid\/ciz938"},{"key":"ref_98","unstructured":"Chemical Book GSK 2838232 (2020, August 18). Full IUPAC Chemical Name: 4-(((3R,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((4-chlorobenzy1)(2-(dimethylamino)ethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,1a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid. Available online: https:\/\/www.chemicalbook.com\/ProductChemicalPropertiesCB12664173_EN.htm."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Johnson, M., Jewell, R.C., Gan, J., Dumont, E., Burns, O., and Johns, B.A. (2020). A Phase 1 study to assess the relative bioavailability, food effect, and safety of a tablet formulation of GSK2838232, a novel HIV maturation inhibitor in healthy participants after single and repeated doses. Clin. Pharmacol. Drug Dev.","DOI":"10.1002\/cpdd.820"},{"key":"ref_100","unstructured":"(2020, July 15). Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03045861."},{"key":"ref_101","unstructured":"Burke, M.D. (2018, January 4\u20137). Transforming the Patient Experience through Long Acting Injectable\/Implantable Formulations: New Opportunities and Technologies. Proceedings of the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Conference, Washington, DC, USA."},{"key":"ref_102","unstructured":"Burke, M.D., McQueen, L., and Rusk, S. (2019). Ionic Liquid salts of 4-4-(((3R,5aR,5bR,7aR,9S,11aR,11bR,13aS)-3a-((R)-2-((4-chlorobenzy1)(2-(dimethylamino)ethyl)amino)-l-hydroxyethyl)-l-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,1a,11b,12,13,13a-octadecahydro-2H-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid. (WIPO (PCT) Patent WO2019186342A1)."},{"key":"ref_103","unstructured":"Akhavein, N., and Velthuisen, E. (2018, January 21\u201325). Novel parenteral platforms for tunable long-acting administration of hydrophobic HIV compound. Proceedings of the HIV Research for Prevention Conference, (PD09.02), Madrid, Spain."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1039\/b925147b","article-title":"Confused ionic liquid ions\u2014A \u201cliquification\u201d and dosage strategy for pharmaceutically active salts","volume":"46","author":"Bica","year":"2010","journal-title":"Chem. Commun."},{"key":"ref_105","unstructured":"Rogers, R.D., Daly, D.T., MacFarlane, D., Scott, J.L., Seddon, K.R., Gurau, G., Bica, K., Turanjanin, J., and Dean, P.M. (2009). Dual functioning ionic liquids and salts thereof. (U.S. Patent 9,278,134)."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Pannu, J. (2020, July 15). Running ahead of Pandemics: Achieving in-advance Antiviral Drugs. Available online: https:\/\/www.mercatus.org\/publications\/covid-19-crisis-response\/running-ahead-pandemics-achieving-advance-antiviral-drugs.","DOI":"10.2139\/ssrn.3570737"},{"key":"ref_107","unstructured":"(2020, July 15). Prescribing Information for Zovirax \u00ae (Acyclovir), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/018828s031lbl.pdf."},{"key":"ref_108","unstructured":"AHFS Drug Information American Society of Hospital Pharmacists (AHFS) (2020, July 15). Bethesda MD 765. Available online: http:\/\/www.ahfsdruginformation.com\/."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0378-5173(96)04601-7","article-title":"Polymorphism and pseudopolymorphism: Influencing the dissolution properties of the guanine derivative Acyclovir","volume":"139","author":"Kristl","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1023\/A:1014224900524","article-title":"Experimental and computational screening models for prediction of aqueous drug solubility","volume":"19","author":"Bergstrom","year":"2002","journal-title":"Pharm. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/10717544.2013.853213","article-title":"Enhanced oral bioavailability of Acyclovir by inclusion complex using hydroxypropyl-\u03b2-cyclodextrin","volume":"21","author":"Nair","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_112","unstructured":"Budavari, S., O\u2019Neil, M., Smith, A., Heckelman, P., and Obenchain, J. (1996). The Merck Index, Merck & Co.. [12th ed.]."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6002\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:10Z","timestamp":1760177050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":112,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176002"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176002","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}